uniQure (QURE) Insider Jack Kaye Sells $225K of Stock
Jack Kaye recently parted with 5,295 shares of uniQure N.V., adding to a notable stretch of insider transactions at the biotech firm.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jack Kaye sold 5,295 shares of uniQure N.V. ($QURE) at an average price of $42.57, worth about $225,408.15, on June 17, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $QURE is up 1.4% after 1 week, down 16.4% after 1 month and down 54.8% to date (from the $48.16 close on Jun 17, 2026).
QURE
uniQure N.V.
Key Points
- Jack Kaye sold 5,295 shares of uniQure N.V. (NasdaqGS: QURE) at an average price of $42.57 on June 17, 2026, for a total value of $225,408.15.
- The stock changes hands at $45.77, well clear of its 52-week low of $8.73 while heading toward its next earnings report scheduled for November 9, 2026.
- Wall Street maintains a strong buy consensus with a mean target of $61.46 across 12 analyst opinions, following recent updates from firms like Barclays and RBC Capital.
Get $QURE trade alerts by text
We text you when insiders, Congress or big funds trade $QURE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated uniQure N.V. alert may contain errors. Disclosures
Jack Kaye Executes Share Sale in uniQure N.V.
Jack Kaye parted with 5,295 shares of uniQure N.V. (NasdaqGS: QURE) on June 17, 2026. The transaction took place at an average price of $42.57, bringing the total value of the trade to $225,408.15 according to a regulatory filing with the Securities and Exchange Commission.
Stock Performance and Recent Range
The shares currently change hands at $45.77, maintaining a comfortable distance above the 52-week low of $8.73 while trading below the high of $71.50. The company's 50-day moving average rests at $40.20, with the 200-day moving average trailing at $29.66. Investors are keeping a close watch on these trading bands as the company prepares its upcoming quarterly financial update.
Executive Trading Activity
This transaction joins a busy period of insider trades at the biotechnology firm. CEO Matthew Kapusta made headlines earlier in June with multiple transactions, including the purchase of 62,581 shares on June 17, 2026, at $19.39 each alongside planned sales. Chief Medical Officer Walid Abi-Saab also sold 1,434 shares at $46.86 on June 26, 2026, for a total of $67,197.24.
Wall Street Ratings and Price Targets
Wall Street firms continue to adjust their outlooks on the company. On October 5, 2026, Barclays lowered its target to $28.00 from $60.00 while shifting the stock to an equal-weight rating. RBC Capital maintained an outperform rating on October 2, 2026, moving its target to $48.00 from $65.00. Goldman Sachs kept a neutral rating on September 30, 2026, setting its target at $31.00. Earlier in the summer, HC Wainwright kept a buy rating with an $80.00 target on June 29, 2026, and Mizuho kept an outperform rating with a $68.00 target on June 25, 2026. The stock currently holds a consensus strong buy rating with a mean price target of $61.46 across 12 analyst opinions.
Focus on Gene Therapies in Amsterdam
Based in Amsterdam, the Netherlands, uniQure N.V. develops specialized gene therapies targeting rare and severe medical conditions, including treatments for hemophilia B and Huntington's disease. The company relies on its clinical pipeline to advance therapies through early-stage trials. Because the company is not currently profitable, it has no meaningful forward price-to-earnings ratio.
What to Watch at uniQure N.V.
Market participants will look ahead to uniQure's financial report on November 9, 2026, to gauge the progress of its clinical programs and cash reserves. Additional Form 4 filings will provide further insight into executive buying and selling habits as the year draws to a close.
Related Filing Alerts
Source: Jack Kaye's Form 4 filing on $QURE (Jun 17, 2026). Find the original filing: QURE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts